

Diagnostic Conflicts Test Pathological Persistence

BY SHERRY BOSCHERT
San Francisco Bureau

SAN FRANCISCO — When a dermatopathologist butts heads with a pathologist over a diagnosis, it helps to keep the patient in mind.

“What do you do when your opinion differs radically from that of the contributing pathologist?” asked Dr. Dirk M. Elston, director of dermatology at Gei-

singer Medical Center, Danville, Pa. “You’re getting cases ... from all over the country. What you get to look at is sometimes not what the contributor thought. Sometimes it’s a sticky situation.”

Persistence in the face of diagnostic conflicts—especially when a malignancy is at issue—may be needed to achieve the appropriate treatment. “As long as we keep the patient in mind, we’re doing the right thing,” said Dr. Elston, who mod-

erated a session at the annual meeting of the American Society of Dermatopathology in which speakers gave examples of cases in which their diagnostic opinions differed from others.

Dr. Ronald P. Rapini described an elderly male patient who had a spindle cell neoplasm on his face in the background of solar elastosis. The biopsy showed relatively bland spindle cells going through the fibrotic sun-damaged dermis. Some

areas showed cells that were a little bit atypical, but not strikingly so.

When he looked around the sample more, however, he saw progressively more atypical cells and eventually diagnosed an atypical fibroxanthoma, using the appropriate diagnostic stains, recalled Dr. Rapini, professor and chair of dermatology at the University of Texas M.D. Anderson Cancer Center, Houston.

The patient decided to see a head and neck surgeon at another institution, which requested the biopsy slides for review by their own pathologist. “I’ll call him Dr. B, because he diagnosed it as benign,” Dr. Rapini said. Dr. B told the head

EpiCeram® Skin Barrier Emulsion

Rx only
For Topical Dermatological Use Only

Product Description

EpiCeram® Skin Barrier Emulsion is a steroid-free, fragrance-free, ceramide-dominant formulation.

Indications for Use

EpiCeram Skin Barrier Emulsion is to be used to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including atopic dermatitis, irritant contact dermatitis, and radiation dermatitis. EpiCeram Skin Barrier Emulsion helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

Contraindications

EpiCeram Skin Barrier Emulsion is contraindicated in persons with known hypersensitivity to any of the components of the formulation.

Warnings

EpiCeram Skin Barrier Emulsion does not contain a sunscreen and should always be used in conjunction with a sunscreen in sun exposed areas. In radiation dermatitis and/or in conjunction with ongoing radiation therapy apply following radiation therapy. Do not apply within 4 hours prior to radiation therapy. Apply twice daily or as indicated by the radiation therapist. After application, a temporary tingling sensation may occur (10 to 15 minutes). Keep this and similar products out of the reach of children. Follow directions for use. If condition does not improve within 10 to 14 days, consult physician.

Precautions and Observations

For the treatment of any dermal wound, consult a physician.

- Use EpiCeram Barrier Emulsion only as directed
- EpiCeram Skin Barrier Emulsion is non-toxic, however it is for external use only and should not be ingested or taken internally
- If clinical signs of infection are present, appropriate treatment should be initiated. If clinically indicated, use of EpiCeram Skin Barrier Emulsion may be continued during the anti-infective therapy
- If the condition does not improve within 10 to 14 days, consult a physician
- EpiCeram Skin Barrier Emulsion does not contain a sunscreen and should always be used in conjunction with a sunscreen in sun exposed areas
- In radiation dermatitis and/or in conjunction with ongoing radiation therapy, apply following radiation therapy
- Do not apply within 4 hours prior to radiation therapy
- Apply twice daily or as indicated by the radiation therapist
- Following the application of EpiCeram Skin Barrier Emulsion a temporary tingling sensation may occur (10 to 15 minutes)
- Keep this and other similar products out of the reach of children

Instructions for Use

Apply a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin. If the skin is broken, cover EpiCeram Skin Barrier Emulsion with a dressing of choice.

Ingredients

Capric Acid, Cholesterol, Citric Acid, Conjugated Linoleic Acid, Dimethicone, Disodium EDTA, E. Cerifera (Candelilla) Wax, Food Starch Modified Corn Syrup Solids, Glycerin, Glyceryl Stearate, Hydroxypropyl Bispalmitamide MEA (Ceramide), Palmitic Acid, PEG-100 Stearate, Petrolatum, Phenoxyethanol, Potassium Hydroxide, Purified Water, Sorbic Acid, Squalane, Xanthan Gum.

How Supplied

EpiCeram Skin Barrier Emulsion is available in a 90 gram tube. NDC 67857-800-90. Store at 15°C to 30°C (59°F to 86°F). Do not freeze.

Marketed by

Promius Pharma, LLC
Bridgewater, NJ 08807
U.S. Patent No. 5,643,899

EPI CERAM is a registered trademark of Ceragenix Pharmaceuticals, Inc.

Rx only – Prescription Medical Device; Federal Law restricts this device to sale by or on the order of a physician.



Persistence in the face of diagnostic conflicts may be needed to achieve the appropriate treatment.

DR. ELSTON

and neck surgeon that the patient had a benign lesion that didn’t need excision.

“What would you do?” Dr. Rapini asked. He called a dermatopathologist at the other institution—“I’ll call him Dr. C”—and asked him to talk with Dr. B, the pathologist, to request that he at least put an addendum on his report to acknowledge that there was an alternative opinion saying this might be an atypical fibroxanthoma and that it was not a clear-cut case. “So maybe the head and neck surgeon might actually remove the lesion,” Dr. Rapini said.

Dr. C reviewed the case and agreed that the lesion looked like an atypical fibroxanthoma. He did speak with Dr. B, but Dr. B refused to modify his pathology report in any way, insisting that this was a benign lesion. Although both Dr. B and Dr. C worked at the same institution, Dr. C felt it would be inappropriate for Dr. C to make an addendum himself on a colleague’s case.

“Now what would you do?” Dr. Rapini asked. He asked Dr. C to talk to the head of his institution’s pathology department to see what the chair would say. “The actions of the head of the department are not known to me,” Dr. Rapini said. The pathology report basically stayed the same.

“Now what would you do?” he repeated. Dr. Rapini called the head and neck surgeon directly to inform him of the alternative opinion, and that Dr. Rapini had diagnosed the lesion as an atypical fibroxanthoma that should be removed.

The surgeon reexcised the area and sent the surgical specimen to the institution’s dermatopathologist, who declared it an atypical fibroxanthoma with clear surgical margins. “So it had a happy ending,” Dr. Rapini said.

Dr. Elston praised him for sticking with the case: “You were willing to persist, and kept in mind that there was a patient at the other end who had a malignancy that was not being treated appropriately.” ■